TY - JOUR
T1 - Diagnosis and management of bone fragility in diabetes
T2 - an emerging challenge
AU - on behalf of the Bone and Diabetes Working Group of IOF
AU - Ferrari, S. L.
AU - Abrahamsen, B.
AU - Napoli, N.
AU - Akesson, K.
AU - Chandran, M.
AU - Eastell, R.
AU - El-Hajj Fuleihan, G.
AU - Josse, R.
AU - Kendler, D. L.
AU - Kraenzlin, M.
AU - Suzuki, A.
AU - Pierroz, D. D.
AU - Schwartz, A. V.
AU - Leslie, W. D.
AU - Ferrari, S. L.
AU - Ardawi, M. S.M.
AU - Cooper, C.
AU - Mithal, A.
N1 - Funding Information:
We are grateful to the Committee of Scientific Advisors of the International Osteoporosis Foundation for their review and endorsement of this paper. This study was supported by an unrestricted grant from MSD. The sponsor did not have any role in preparation, review or approval of the manuscript. SL Ferrari, B Abrahamsen, K Akesson, MSM Ardawi, M Chandran, C Cooper, R Eastell, G El-Hajj Fuleihan, R Josse, DL Kendler, M Kraenzlin, WD Leslie, A Mithal, N Napoli, A Suzuki, AV Schwartz. S Ferrari has received research grants, honoraria, and/or consultancies from Amgen, UCB, MSD, Labatec, Agnovos. B Abrahamsen has received research contracts with Novartis and UCB with funds paid to the institution. D Kendler has received research grants, honoraria, and/or consultancies from Amgen, Eli Lilly, AstraZeneca, Pfizer. R Eastell has received research grants from Alexion, Amgen Inc., and Ultragenyx, and consulting fees from Immunodiagnostic Systems, GlaxoSmithKline, and Amgen Inc. A Suzuki has received research grants and/or honoraria from Astellas, Chugai, Daiichi-Sankyo, Kyowa-Hakko Kirin, MSD, Novo Nordisk, Ono, Pfizer, Taisho Toyama, Tanabe-Mitsubishi and Takeda. R Josse has received consultancy fees and speaker honoraria from Amgen, Lilly, Merck. K Akesson has received lecture fees or consultancies from MSD, UCB, Amgen, Eli Lilly and Sandoz. A Schwartz has received a research grant from Hologic and consulting fees from Amgen. N Napoli has received consulting fees from Lilly and Amgen. G El-Hajj Fulehain, M Chandran, DD Pierroz, M Kraenzlin have no disclosure.
Funding Information:
Acknowledgements We are grateful to the Committee of Scientific Advisors of the International Osteoporosis Foundation for their review and endorsement of this paper. This study was supported by an unrestricted grant from MSD. The sponsor did not have any role in preparation, review or approval of the manuscript.
Funding Information:
Conflict of interest S Ferrari has received research grants, honoraria, and/or consultancies from Amgen, UCB, MSD, Labatec, Agnovos. B Abrahamsen has received research contracts with Novartis and UCB with funds paid to the institution. D Kendler has received research grants, honoraria, and/or consultancies from Amgen, Eli Lilly, AstraZeneca, Pfizer. R Eastell has received research grants from Alexion, Amgen Inc., and Ultragenyx, and consulting fees from Immunodiagnostic Systems, GlaxoSmithKline, and Amgen Inc. A Suzuki has received research grants and/or honoraria from Astellas, Chugai, Daiichi-Sankyo, Kyowa-Hakko Kirin, MSD, Novo Nordisk, Ono, Pfizer, Taisho Toyama, Tanabe-Mitsubishi and Takeda. R Josse has received consultancy fees and speaker honoraria from Amgen, Lilly, Merck. K Akesson has received lecture fees or consultancies from MSD, UCB, Amgen, Eli Lilly and Sandoz. A Schwartz has received a research grant from Hologic and consulting fees from Amgen. N Napoli has received consulting fees from Lilly and Amgen. G El-Hajj Fulehain, M Chandran, DD Pierroz, M Kraenzlin have no disclosure.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification and management of diabetic patients at increased fracture risk.
AB - Fragility fractures are increasingly recognized as a complication of both type 1 and type 2 diabetes, with fracture risk that increases with disease duration and poor glycemic control. Yet the identification and management of fracture risk in these patients remains challenging. This review explores the clinical characteristics of bone fragility in adults with diabetes and highlights recent studies that have evaluated bone mineral density (BMD), bone microstructure and material properties, biochemical markers, and fracture prediction algorithms (i.e., FRAX) in these patients. It further reviews the impact of diabetes drugs on bone as well as the efficacy of osteoporosis treatments in this population. We finally propose an algorithm for the identification and management of diabetic patients at increased fracture risk.
UR - http://www.scopus.com/inward/record.url?scp=85051441673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051441673&partnerID=8YFLogxK
U2 - 10.1007/s00198-018-4650-2
DO - 10.1007/s00198-018-4650-2
M3 - Review article
C2 - 30066131
AN - SCOPUS:85051441673
VL - 29
SP - 2585
EP - 2596
JO - Osteoporosis International
JF - Osteoporosis International
SN - 0937-941X
IS - 12
ER -